Canaloplasty 2-year clinical results published

Article

Results of the evaluation of two-year post-surgical safety and efficacy of canaloplasty to treat open angle glaucoma (OAG) have been published in the Journal of Cataract and Refractive Surgery. Dr Richard A Lewis et al., concluded that the procedure was safe and effective in reducing IOP in adult OAG patients.

Results of the evaluation of two-year post-surgical safety and efficacy of canaloplasty (circumferential viscodilation and tensioning of the inner wall of Schlemm canal) to treat open angle glaucoma (OAG) have been published in the Journal of Cataract and Refractive Surgery. Dr Richard A Lewis et al., concluded that the procedure was safe and effective in reducing IOP in adult OAG patients.

One hundred and twenty seven patients took part in the clinical study and each patient was enrolled to have the canaloplasty procedure using a flexible microcatheter. At the end of two years the mean IOP of 16.0 mmHg ± 4.2 (SD) and the mean glaucoma medication use of 0.5 ± 0.8. Those eyes with canaloplasty alone were reported as have a mean IOP of 16.3 ± 3.7 mmHg and 0.6 ± 0.8 medications.

As Ophthalmology Times Europe reported as far back as 2006 when we spoke with head researcher, Dr Richard Lewis non-penetrating surgery is becoming more widely accepted in Europe: "I do not feel that uneasiness relating to a lack of knowledge or training is a significant obstacle or barrier to uptake as this unique approach appears far healthier and safer for the eye than trabeculectomy while providing better IOP control." Dr Lewis's results appear to bear out his statement. We will be talking to Dr Lewis in greater depth about the piece in the near future.

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.